2-Year Patient-Related Versus Stent-Related Outcomes The SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial by Jensen, Lisette Okkels et al.
Journal of the American College of Cardiology Vol. 60, No. 13, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00CLINICAL RESEARCH Interventional Cardiology
2-Year Patient-Related
Versus Stent-Related Outcomes
The SORT OUT IV (Scandinavian Organization
for Randomized Trials With Clinical Outcome IV) Trial
Lisette Okkels Jensen, MD, DMSCI, PHD,* Per Thayssen, MD, DMSCI,*
Evald Høj Christiansen, MD, PHD,† Hans Henrik Tilsted, MD,‡ Michael Maeng, MD, PHD,†
Knud Nørregaard Hansen, MD,* Anne Kaltoft, MD, PHD,† Henrik Steen Hansen, MD, DMSCI,*
Hans Erik Bøtker, MD, DMSCI, PHD,† Lars Romer Krusell, MD, Jan Ravkilde, MD, DMSCI,‡
Morten Madsen, MSC,§ Leif Thuesen, MD, DMSCI,† Jens Flensted Lassen, MD, PHD,†
for the SORT OUT IV Investigators
Odense, Aarhus, and Aalborg, Denmark
Objectives There are limited head-to-head randomized data on patient-related versus stent-related outcomes for
everolimus-eluting stents (EES) and sirolimus-eluting stents (SES).
Background In the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) trial, comparing
the EES with the SES in patients with coronary artery disease, the EES was noninferior to the SES at 9 months.
Methods The primary endpoint was a composite: cardiac death, myocardial infarction (MI), definite stent thrombosis, or
target vessel revascularization. Safety and efficacy outcomes at 2 years were further assessed with specific fo-
cus on patient-related composite (all death, all MI, or any revascularization) and stent-related composite out-
comes (cardiac death, target vessel MI, or symptom-driven target lesion revascularization). A total of 1,390 pa-
tients were assigned to receive the EES, and 1,384 patients were assigned to receive the SES.
Results At 2 years, the composite primary endpoint occurred in 8.3% in the EES group and in 8.7% in the SES group (hazard
ratio [HR]: 0.94, 95% confidence interval [CI]: 0.73 to 1.22). The patient-related outcome: 15.0% in the EES group
versus 15.6% in the SES group, (HR: 0.95, 95% CI: 0.78 to 1.15), and the stent-related outcome: 5.2% in the EES
group versus 5.3% in the SES group (HR: 0.97, 95% CI: 0.70 to 1.35) did not differ between groups. Rate of definite
stent thrombosis was lower in the EES group (0.2% vs. 0.9%, (HR: 0.23, 95% CI: 0.07 to 0.80).
Conclusions At 2-year follow-up, the EES was found to be noninferior to the SES with regard to both patient-related and stent-
related clinical outcomes. (The SORT OUT IV TRIAL [SORT OUT IV]; NCT00552877) (J Am Coll Cardiol 2012;60:
1140–7) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.004In percutaneous coronary interventions (PCI), drug-eluting
stent (DES) implantation has reduced the need for repeat
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September 25, 2012:1140–7 EES Versus SESdebate continues on the safety of first-generation DES,
given the potential for late stent thrombosis, especially after
discontinuation of dual antiplatelet therapy (2). The first
commercially available second-generation DES, the
zotarolimus-eluting Endeavor stent (Medtronic, Minneap-
olis, Minnesota), did not appear superior to the sirolimus-
eluting stent (SES) in routine practice (3), whereas the next
second-generation DES, the everolimus-eluting stent
(EES) (4–6), zotarolimus-eluting Resolute (7) stent
Medtronic), and the biolimus-eluting (8) stent, have
howed reduced target vessel failure and a lower rate of
tent thrombosis within the first year. The SORT OUT
V (Scandinavian Organization for Randomized Trials
ith Clinical Outcome IV) trial aimed to compare the
afety and efficacy outcomes at 2 years with specific focus
n patient-related composite and stent-related composite
utcomes of the first-generation SES Cypher Select
Cordis, Bridgewater, New Jersey) and the second-
eneration EES Xience V/Promus stent (Abbott Vascu-
ar, Santa Clara, California; Abbott’s privately-labeled
IENCE V Everolimus Eluting Coronary Stent System
istributed by Boston Scientific Corporation) in a
opulation-based setting, using registry detection of clin-
cally driven events.
ethods
atients and study design. SORT OUT IV is a random-
zed, multicenter, single-blind, all-comer, 2-arm, noninfe-
iority trial comparing the EES with the SES in treating
therosclerotic coronary artery lesions. The study period was
ugust 2007 to June 2009. The detailed study protocol can
e found in the main publication (9).
ndpoints. Definition of endpoints are provided elsewhere
9). The primary endpoint was a combination of safety
cardiac death, myocardial infarction [MI], definite stent
hrombosis) and efficacy (clinically indicated target vessel
evascularization) parameters within 9 months of stent
mplantation. In the present study, we further focused on
atient-related composite (all death, all MI, or any revas-
ularization) and stent-related composite outcomes (cardiac
eath, target vessel MI, or symptom-driven target lesion
evascularization). Individual components of the primary
ndpoint comprised the secondary endpoints, and stent
hrombosis was classified according to the Academic Re-
earch Consortium definition (10).
linical event detection. Clinically driven event detection
as used. Data on mortality, hospital admission, coronary
ngiography, repeat PCI, and coronary bypass surgery were
btained for all randomly allocated patients from the na-
ional Danish administrative and healthcare registries
11,12). An independent event committee, whose members
ere blinded to treatment group assignment, adjudicated all
ndpoints.
tatistical analysis. Distributions of continuous variables
ere compared between study groups using the 2-sample t stest or the Mann-Whitney U
test. Distributions of categorical
variables were compared using
the chi-square test. In analyses of
every endpoint, follow-up con-
tinued until the date of an end-
point event, death, emigration,
or 24 months after stent implan-
tation, whichever came first. Sur-
vival curves were constructed
based on time to events, account-
ing for the competing risk of
death (13). Hazard ratios (HR)
were computed using Cox pro-
portional hazards regression
analysis. We performed 2-sided 95% confidence intervals
(CI) and 2-sided p values for superiority for all endpoints.
A 2-sided p value of 0.05 was considered to indicate
statistical significance. Analyses were conducted using
SAS software (version 9.2, SAS Institute, Cary, North
Carolina).
Results
A total of 2,774 patients with 3,584 lesions were randomly
assigned to receive either the EES (1,390 patients with
1,805 lesions) or the SES (1,384 patients with 1,779
lesions). Three patients were lost to follow-up. The trial’s
flow diagram is provided in Figure 1. Baseline and lesion
characteristics are summarized in Tables 1 and 2.
At 2 years, the composite primary endpoint occurred in
114 patients (8.3%) in the EES group and in 120 patients
(8.7%) in the SES group (HR: 0.94, 95% CI: 0.73 to 1.22)
(Fig. 2, Table 3). The patient-related outcome: 202 (15.0%)
patients treated with the EES versus 211 (15.6%) patients
treated with the SES (HR: 0.95, 95% CI: 0.78 to 1.15), and
the stent-related outcome: 70 (5.2%) patients treated with
the EES versus 72 (5.3%) patients treated with the SES
(HR: 0.97, 95% CI: 0.70 to 1.35) did not differ between
groups (Fig. 2, Table 3).
At 2 years, the rate of definite stent thrombosis was lower
in the EES group (3 [0.2%] patients versus 13 [0.9%]
patients, [HR: 0.23, 95% CI: 0.07 to 0.80]) (Fig. 3, Table 3).
ery late definite stent thrombosis was seen in 1 patient in
he EES group and in 4 patients in the SES group (HR:
.25, 95% CI: 0.03 to 2.22). Among patients with definite
r probable stent thrombosis within the first year, 22 of 22
atients (100%) were in dual antiplatelet therapy with
spirin and clopidogrel (Table 4). Patients with very late
efinite stent thrombosis were all on monotherapy with
spirin, and 3 of 5 patients had stopped clopidogrel within
, 3, and 5 weeks, respectively, before the event with very
ate definite stent thrombosis. Of the patients with acute
efinite stent thrombosis, all 3 patients were treated for
Abbreviations
and Acronyms
CI  confidence interval
DES  drug eluting
stent(s)
EES  everolimus-eluting
stent(s)
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)table angina pectoris with a SES. These patients were all
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EES Versus SES September 25, 2012:1140–7treated with aspirin for at least a week before the PCI
procedure, and clopidogrel was initiated on the day of the
PCI procedure (before the intervention).
Figure 1 Patient Flow Diagram in the SORT OUT IV Trial
A total of 2,774 patients were enrolled in the SORT OUT IV trial and randomized t
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Eve
Age, yrs
Men
Diabetes mellitus
Arterial hypertension
Hypercholesterolemia
Current smoker
Body mass index, kg/m2
Previous myocardial infarction
Previous percutaneous coronary intervention
Previous coronary artery bypass grafting
Indication for percutaneous coronary intervention
ST-segment elevation myocardial infarction
Non–ST-segment elevation myocardial infarction
or unstable angina
Stable angina
OtherValues are mean  SD, n (%), or n/total N (%).Clinically driven target lesion revascularization was per-
formed in 40 patients (2.9%) in the EES group and in 49
patients (3.5%) in the SES group (HR: 0.81, 95% CI: 0.53
limus-eluting stents (n  1,390) or sirolimus-eluting stents (n  1,384).
pulation
s-Eluting Stent
 1,390)
Sirolimus-Eluting Stent
(n  1,384) p Value
.2 10.9 64.0 10.8 0.68
,055 (75.9%) 1,041 (75.2%) 0.68
,390 (14.0%) 196/1,384 (14.2%) 0.88
,215 (56.7%) 649/1,207 (53.8%) 0.15
,218 (71.1%) 859/1,208 (71.1%) 1.00
,178 (29.2%) 353/1,162 (30.4%) 0.53
.5 4.7 27.4 4.4 0.43
,223 (22.6%) 259/1,214 (21.3%) 0.46
,227 (21.5%) 250/1,214 (20.6%) 0.58
,227 (9.6%) 97/1,214 (8.0%) 0.16
0.46
122 (8.8%) 145 (10.5%)
458 (32.9%) 453 (32.7%)
773 (55.6%) 754 (54.4%)
37 (2.7%) 32 (2.3%)o everondy Po
rolimu
(n
64
1
194/1
689/1
866/1
344/1
27
276/1
264/1
118/1
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September 25, 2012:1140–7 EES Versus SESto 1.23) (Table 3, Fig. 3). In patients treated with EES, 5
patients with in-stent restenosis presented with non–ST-
segment elevation MI, whereas the clinical presentation in
SES-treated patients with clinically symptoms of in-stent
restenosis was stable angina pectoris.
Discussion
Our trial provides the first long-term head-to-head ran-
domized comparison of the EES versus the SES. At 9
months follow-up, we documented noninferiority of the
EES overall; and across a variety of patient and lesion
subgroups, the 2 treatments yielded similar composite end-
point results. This result was maintained at 2 years for the
primary endpoint. We further focused on patient-related
Baseline Lesion and Procedure CharacteristicsTable 2 Baseline Lesion and Procedure Cha
Everolimus-E
(n  1
Number of lesions 1,8
Target lesions per patient
1 1,062
2 256
3 60
3 12
No. per patient 1.3
Target vessel location
Left main artery 37
Left anterior descending artery 738
Left circumflex artery 434
Right artery 581
Saphenous vein graft 15
Lesion type
A 287
B1 489
B2 351
C 678
Chronic total occlusion lesions 111
Bifurcation lesions 215
Lesion length 18 mm 557
Lesion length, mm
Mean 16.5
Range 0.0 –
Reference vessel size, mm 3.2
No. of stents
Per patient 1.6
Per lesion 1.3
Total stent length, mm
Per patient 26.4
Per lesion 20.3
Direct stenting 403
Stent delivery failure 53
Maximum pressure, atm 16.4
Length of procedure, min 27.3
Fluoroscopy time, min 9.2
Contrast, ml 121.5
Use of glycoprotein IIb/IIIa inhibitors 213
Values are mean  SD, or n (%), or median (interquartile range).and stent-related composite outcomes, where the 2 stentsalso showed similar clinical outcomes except for the rate of
definite stent thrombosis, which was lower in the EES
group.
The second-generation EES has previously been com-
pared with the first-generation paclitaxel-eluting stents in
the COMPARE (A Trial of Everolimus-Eluting Stents and
Paclitaxel-Eluting Stents for Coronary Revascularization in
Daily Practice) trial (6) and the SPIRIT IV (Clinical
Evaluation of the XIENCE V Everolimus Eluting Coro-
nary Stent System) trial (4), where both studies showed a
lower target vessel failure rate in the EES group after 2 years
compared with the paclitaxel-eluting stent group. The
target vessel failure rates for the EES group of 6.9% in the
COMPARE trial (6) and 9.0% in the SPIRIT IV trial (4)
ristics
Stent Sirolimus-Eluting Stent
(n  1,384) p Value
1,779
0.85
) 1,072 (77.5%)
) 244 (17.6%)
) 54 (3.9%)
) 14 (1.0%)
1.3 (0.6) 0.56
0.08
) 25 (1.4%)
) 805 (45.3%)
) 397 (22.3%)
) 537 (30.2%)
) 15 (0.8%)
0.57
%) 265 (14.9%)
%) 499 (28.0%)
) 324 (18.2%)
) 691 (38.8%)
) 105 (6.1%) 0.78
) 217 (12.7%) 0.76
528 29.7 0.44
16.9 (12.0) 0.32
2.0 – 120.0
.6) 3.2 (3.0–3.5) 0.06
1.6 (0.9) 0.21
1.2 (0.6) 0.26
26.6 18.2 0.78
20.7 12.9 0.38
) 361 (20.4%) 0.14
) 36 (2.0%) 0.08
17.6 4.2 0.001
27.9 20.6 0.45
9.7 9.2 0.13
124.1 87.3 0.42
) 234 (16.9%) 0.26racte
luting
,390)
05
(76.4%
(18.4%
(4.3%
(0.9%
(0.6)
(2.0%
(40.9%
(24.0%
(32.2%
(0.8%
(15.9
(27.1
(19.4%
(37.6%
(6.4%
(12.3%
 30.9
(11.0)
90.0
(3.0–3
(1.0)
(0.6)
 17.5
 12.3
(22.4%
(2.9%
 4.2
 20.0
 8.6
 85.5
(15.3%were comparable to our results after 2 years. The rate of very
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EES Versus SES September 25, 2012:1140–7late definite stent thrombosis was comparable between the 3
studies in the EES groups, with 3 cases (0.3%) in the
COMPARE trial (6), 2 (0.1%) in the SPIRIT IV trial (4),
and 1 (0.1%) in our study. A similar result was observed in
the RESOLUTE (RESOLUTE-III All-Comers Trial: A
Figure 2 Major Adverse Cardiac Events: Patient- and Stent-Rel
(A) Time-to-event curves for major adverse cardiac events (a composite of cardiac
tion). (B) Time-to-event curves for patient-related (all death, all myocardial infarctio
get vessel myocardial infarction, or symptom-driven target lesion revascularization
Clinical OutcomesTable 3 Clinical Outcomes
Events at 2 Years*
Everolimus-Eluting Stent
(n  1,390)
Patient-related outcome 202 (15.6)
Stent-related outcome 70 (5.2)
Composite endpoint 114 (8.3)
Death
All-cause mortality 71 (5.1)
Cardiac 31 (2.2)
Non-cardiac 40 (2.9)
Myocardial infarction 25 (1.8)
Myocardial infarction—target vessel related 11 (0.8)
Myocardial infarction—non-target vessel related 14 (1.0)
Stent thrombosis§
Definite 3 (0.2)
Acute (24 h) 0 (0.0)
Subacute (24 h to 30 days) 2 (0.1)
Late (30 days to 12 months) 0 (0.0)
Very late (12 months) 1 (0.1)
Probable 7 (0.5)
Definite or probable 10 (0.7)
Possible 11 (0.8)
Definite, probable, or possible 21 (1.5)
Target vessel revascularization 76 (5.5)
Target lesion revascularization 40 (2.9)
Non-target vessel revascularization 80 (5.8)
Any revascularization 131 (9.4)Values are n (%). *Primary endpoint. Composite of major adverse cardiac events: cardiac death, myocardi
a Cox regression model. ‡Two-sided from a Cox regression model. §Academic Research Consortium defiRandomized Comparison of a Zotarolimus-Eluting
Stent With an Everolimus-Eluting Stent for Percutane-
ous Coronary Intervention) trial (7), in which the EES
was associated with significantly less definite stent
thrombosis than the zotarolimus-eluting stent (Resolute)
Outcomes
, myocardial infarction, definite stent thrombosis, and target vessel revasculariza-
ny revascularization) and stent-related composite outcomes (cardiac death, tar-
Sirolimus-Eluting Stent
(n  1,384)
Hazard Ratio†
(95% Confidence Interval) p Value‡
211 (15.6) 0.95 (0.78–1.15) 0.58
72 (5.3) 0.97 (0.70–1.35) 0.86
120 (8.7) 0.94 (0.73–1.22) 0.66
66 (4.8) 1.07 (0.77–1.50) 0.67
25 (1.8) 1.24 (0.73–2.10) 0.43
41 (3.0) 0.97 (0.63–1.51) 0.91
31 (2.2) 0.80 (0.47–1.36) 0.41
16 (1.2) 0.68 (0.32–1.47) 0.33
15 (1.1) 0.93 (0.45–1.92) 0.84
13 (0.9) 0.23 (0.07–0.80) 0.02
3 (0.2) — —
4 (0.3) 0.50 (0.09–2.71) 0.42
2 (0.1) — —
4 (0.3) 0.25 (0.03–2.22) 0.21
4 (0.3) 1.74 (0.51–5.96) 0.38
17 (1.2) 0.59 (0.27–1.28) 0.18
6 (0.4) 1.83 (0.68–4.96) 0.23
23 (1.7) 0.91 (0.50–1.64) 0.75
86 (6.2) 0.88 (0.64–1.19) 0.40
49 (3.5) 0.81 (0.53–1.23) 0.33
94 (6.8) 0.84 (0.62–1.13) 0.24
148 (10.7) 0.87 (0.69–1.10) 0.25ated
death
n, or a
).al infarction, definite stent thrombosis, and clinically driven target vessel revascularization. †From
nition.
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September 25, 2012:1140–7 EES Versus SESand the rate of very late definite stent thrombosis was 3
(0.3%). In contrast to the other 2 all-comer trials (6,7),
we did not find any probable stent thrombosis after the
first year. The Danish National Health Service provides
universal tax-supported health care, guaranteeing resi-
dents free access to hospitals along with emergency
medical service transportation, and 1 explanation for the
lack of probable stent thrombosis could be that patients
who had documented acute ischemia in a territory of a
previously implanted stent would be scheduled for a
re-angiogram, either acute or subacute, depending on the
changes in the electrocardiogram.
In the LEADERS (Limus Eluted From A Durable
Versus ERodable Stent Coating) trial (8), an increasing
divergence in outcomes was showed over 4 years in favor of
the biolimus-eluting stent. The rate of very late definite
stent thrombosis was 0.1% in the biolimus-eluting stent
group compared with 0.6% per year from 1 to 4 years in the
SES group. In the ISAR-TEST-4 (Intracoronary Stenting
and Angiographic Results: Test Efficacy of 3 Limus-Eluting
Stents With Different Polymer Coatings) trial (14), which
compared the EES with the SES, clinical events continued
to accrue at a low rate out to 3 years in both groups. There
was no significant difference between the EES and SES
groups with regard to the primary endpoint, and the rate of
definite/probable stent thrombosis did not differ signifi-
cantly between the 2 groups (1.4% vs. 1.9%%). The EX-
CELLENT (Efficacy of Xience/Promus Versus Cypher to
Reduce Late Loss After Stenting) angiographic trial (15)
found EES to be noninferior to SES in inhibition of late
lumen loss after stenting, which was corroborated by similar
rates of clinical outcomes. Rate of stent thrombosis was
numerically lower for EES than for SES within 9 months,
Figure 3 Definite Stent Thrombosis and Target Lesion Revascu
Time-to-event curves for (A) definite stent thrombosis and (B) target lesion revascthough this was not statistically significant.Finally, as composite endpoints in cardiovascular trials
often include a wide range of events, comparison of com-
posite endpoints can be difficult because of the lack of
consensus definitions. We retrospectively combined the
patient-related and stent-related endpoints to compare our
endpoint to that of the all-comer RESOLUTE trial (7). As
in the RESOLUTE trial, we found a substantially high
numerical difference between patient-related and stent-
related outcomes: stent-related outcomes constituted
only one-third of patient-related outcomes for both stent
types in our study. Despite using the same composite
endpoint definition, the rates may still differ between
studies as in the RESOLUTE trial and our study.
Two-thirds of the patient-related outcomes were not
stent related and may be related to disease progression
and noncardiac events (noncardiac death). A long-term
follow-up from the BASKET (Basel Stent Kosten-
Effektivitäts Trial) (16) has recently shown a 25% event
rate after 5 years with new ischemic perfusion defects
detected in 23.3% of the patients, although being silent in
the majority of the patients.
Conclusion
The EES was found to be noninferior to the SES for
patients treated with PCI, accompanied by a lower rate of
definite stent thrombosis.
Reprint requests and correspondence: Dr. Lisette Okkels Jensen,
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